Partner With Us NRI

Laurus Labs acquires stake in ImmunoACT

News: Laurus Labs has signed an investment agreement with Immunoadoptive Cell Therapy (lmmunoACT), an advanced cell and gene therapy company to acquire 26.62% stake, subject to completion of conditions precedent, for a cash consideration of ~ Rs.46 crore. Additionally, the senior management of Laurus Labs would also invest in ImmunoACT for a 5.64% stake for ~ Rs.9.75 crore.

Views: Laurus Labs' investment in ImmunoACT is part of the larger strategy to strengthen the biologics business. This provides the company access and entry into an emerging field of research. CAR-T therapy is a very promising treatment option, which has had success in the western world.

Impact: Positive